Lubrizol's Argireline Amplified Peptide Extends Botox-type Injection Results by 8 Weeks: New Study

Lubrizol's Argireline Amplified Peptide, when applied in combination with Botulinum toxin type-A injections like Botox, can "keep wrinkles at bay for nearly 8 weeks longer than [the injections] alone." This research aligns with consumer demands for effective, longer-lasting dermo-aesthetic solutions, allowing them to make fewer trips to the clinic.

This enhancement and prolonging effect of the ingredient is in line with the rising medicalization of beauty. It also offers further evidence of the peptide beauty revolution.

Argireline Amplified Peptide (INCI: Water (Aqua) (and) Acetyl Hexapeptide-8 (and) Sodium Benzoate), which is produced in accordance to green chemistry principles, has displayed "superior" in vitro activity and muscle relaxation effects compared to the company's original Argireline peptide. It was initially used in topical treatments as a non-invasive solution to reduce facial muscle activity.

A recent study involved 45 Caucasian volunteers, both men and women, aged 35 to 60. Participants received 50 units of Botulinum toxin type A injections targeting crow’s feet, frown lines, and forehead wrinkles. In addition, they applied either a cream containing a 5% Argireline Amplified peptide solution or a placebo cream to their entire face twice daily over a period of four months.

Researchers employed both 2D and 3D facial imaging techniques to assess changes in wrinkle visibility, skin texture, and wrinkle length across key areas such as crow’s feet, frown lines, and the forehead.

The findings revealed that after 1, 3, and 4 months, participants who received the active peptide combination treatment showed a significant reduction in wrinkles compared to those treated with BTA and a placebo. Notably, this combination treatment extended the wrinkle-free period by nearly 8 weeks longer than BTA alone, demonstrating its superior effectiveness.